news
Heparin helps in understanding a natural HIV barrier
23 March 2015 | By Victoria White
Heparin, a blood thinning agent, is helping researchers at the University of East Anglia (UEA) understand more about the body’s natural barriers to HIV...
List view / Grid view
HIV (Human Immunodeficiency Virus)
news
Gilead announces SVR12 rates from Phase 3 study evaluating Harvoni® for the treatment of chronic hepatitis C in patients co-infected with HIV
27 February 2015 | By Gilead Sciences
96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...
news
ALLY trial demonstrates 97% hepatitis C cure rates among patients coinfected with HIV after ribavirin-free investigational 12-week regimen of daclatasvir and sofosbuvir
27 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) coinfected with HIV – a patient population that historically has been challenging to treat in large part due…
news
Fungal disease deaths – just “$30 a person” for major reductions in AIDS globally
26 February 2015 | By GAFFI
Early detection and treatment of fungal meningitis and pneumonia can save hundreds of thousands of lives, for a cost of 'only $30' per HIV patient, the world's first stakeholder meeting on fungal diseases hosted by GAFFI (Global Action Fund for Fungal Infections) and held in Seattle, USA has concluded...
news
New aggressive form of HIV uncovered in Cuba
12 February 2015 | By KU Leuven
Writing in the journal EBioMedicine, researchers at KU Leuven’s Laboratory for Clinical and Epidemiological Virology now report a recombinant form of HIV observed in patients in Cuba that makes this transition much faster...
news
FDA approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults
30 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults...
news
MWV’s MEMS™ System chosen for trials of HIV-prevention medication in Africa and India
2 December 2014 | By MWV
Global packaging company has received a grant from The Bill & Melinda Gates Foundation to improve adherence and accuracy during PrEP trials...
news
ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV
27 November 2014 | By ViiV Healthcare
Landmark number of grants awarded for 2015 as the Positive Action for Children Fund hits 5 year milestone...
news
CHMP announces positive opinion for rezolsta™, a new once-daily, fixed-dose HIV therapy combining darunavir and cobicistat
29 September 2014 | By Janssen
Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a Positive Opinion recommending REZOLSTA™...
news
Roche launches Global Access Program for HIV viral load testing
26 September 2014 | By Roche
Roche announced the launch of a new Global Access Program for HIV viral load testing...
news
Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies
24 September 2014 | By Gilead
Gilead Sciences, Inc. announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives...
news
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
5 September 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets...
news
European Commission approves Gilead Sciences’ Tybost™
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
news
ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1
ViiV Healthcare is pleased to announce that the U.S. FDA has approved Tivicay® (dolutegravir) 50-mg tablets...
news
Baby born with AIDS virus appears to have been cured
3 March 2013 | By University of Mississippi
A baby born with the virus that causes AIDS appears to have been cured, scientists announced Sunday...
